A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517

Mark H. Kirschbaum, Bryan H. Goldman, Jasmine M. Zain, James R. Cook, Lisa M Rimsza, Stephen J. Forman, Richard I. Fisher

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

We performed a phase II study of oral vorinostat (200 mg twice daily, days 114 of a 21-day cycle), a histone and protein deacetylase inhibitor, to examine efficacy and tolerability in patients with relapsed/refractory Hodgkin lymphoma (HL) with ≤ 5 prior therapies. The primary endpoint was the objective response rate (ORR), with secondary endpoints of progression-free survival (PFS), overall survival (OS), safety and tolerability. A two-stage design was used for patient accrual. Twenty-five eligible patients were accrued in the first stage. Median time on treatment was 3.8 months. The ORR was 4% (one partial response). Median PFS was 4.8 months. The drug was well tolerated. The second stage of accrual was not opened due to few objective responses. Oral vorinostat has limited single-agent activity in relapsed/refractory HL. There was one partial response, while seven other patients had stable disease for > 1 year, including two with stable disease for nearly 3 years, suggesting that further studies in combination with other active agents in this setting may be warranted.

Original languageEnglish (US)
Pages (from-to)259-262
Number of pages4
JournalLeukemia and Lymphoma
Volume53
Issue number2
DOIs
StatePublished - Feb 2012

Fingerprint

Hodgkin Disease
Disease-Free Survival
Histone Deacetylase Inhibitors
Therapeutics
Safety
Survival
vorinostat
Pharmaceutical Preparations
Proteins

Keywords

  • Lymphoma and Hodgkin disease
  • Pharmacotherapeutics
  • Signaling therapies

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma : Southwest Oncology Group Study S0517. / Kirschbaum, Mark H.; Goldman, Bryan H.; Zain, Jasmine M.; Cook, James R.; Rimsza, Lisa M; Forman, Stephen J.; Fisher, Richard I.

In: Leukemia and Lymphoma, Vol. 53, No. 2, 02.2012, p. 259-262.

Research output: Contribution to journalArticle

Kirschbaum, Mark H. ; Goldman, Bryan H. ; Zain, Jasmine M. ; Cook, James R. ; Rimsza, Lisa M ; Forman, Stephen J. ; Fisher, Richard I. / A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma : Southwest Oncology Group Study S0517. In: Leukemia and Lymphoma. 2012 ; Vol. 53, No. 2. pp. 259-262.
@article{552705c0721f4e07b414fe07c0222fac,
title = "A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517",
abstract = "We performed a phase II study of oral vorinostat (200 mg twice daily, days 114 of a 21-day cycle), a histone and protein deacetylase inhibitor, to examine efficacy and tolerability in patients with relapsed/refractory Hodgkin lymphoma (HL) with ≤ 5 prior therapies. The primary endpoint was the objective response rate (ORR), with secondary endpoints of progression-free survival (PFS), overall survival (OS), safety and tolerability. A two-stage design was used for patient accrual. Twenty-five eligible patients were accrued in the first stage. Median time on treatment was 3.8 months. The ORR was 4{\%} (one partial response). Median PFS was 4.8 months. The drug was well tolerated. The second stage of accrual was not opened due to few objective responses. Oral vorinostat has limited single-agent activity in relapsed/refractory HL. There was one partial response, while seven other patients had stable disease for > 1 year, including two with stable disease for nearly 3 years, suggesting that further studies in combination with other active agents in this setting may be warranted.",
keywords = "Lymphoma and Hodgkin disease, Pharmacotherapeutics, Signaling therapies",
author = "Kirschbaum, {Mark H.} and Goldman, {Bryan H.} and Zain, {Jasmine M.} and Cook, {James R.} and Rimsza, {Lisa M} and Forman, {Stephen J.} and Fisher, {Richard I.}",
year = "2012",
month = "2",
doi = "10.3109/10428194.2011.608448",
language = "English (US)",
volume = "53",
pages = "259--262",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma

T2 - Southwest Oncology Group Study S0517

AU - Kirschbaum, Mark H.

AU - Goldman, Bryan H.

AU - Zain, Jasmine M.

AU - Cook, James R.

AU - Rimsza, Lisa M

AU - Forman, Stephen J.

AU - Fisher, Richard I.

PY - 2012/2

Y1 - 2012/2

N2 - We performed a phase II study of oral vorinostat (200 mg twice daily, days 114 of a 21-day cycle), a histone and protein deacetylase inhibitor, to examine efficacy and tolerability in patients with relapsed/refractory Hodgkin lymphoma (HL) with ≤ 5 prior therapies. The primary endpoint was the objective response rate (ORR), with secondary endpoints of progression-free survival (PFS), overall survival (OS), safety and tolerability. A two-stage design was used for patient accrual. Twenty-five eligible patients were accrued in the first stage. Median time on treatment was 3.8 months. The ORR was 4% (one partial response). Median PFS was 4.8 months. The drug was well tolerated. The second stage of accrual was not opened due to few objective responses. Oral vorinostat has limited single-agent activity in relapsed/refractory HL. There was one partial response, while seven other patients had stable disease for > 1 year, including two with stable disease for nearly 3 years, suggesting that further studies in combination with other active agents in this setting may be warranted.

AB - We performed a phase II study of oral vorinostat (200 mg twice daily, days 114 of a 21-day cycle), a histone and protein deacetylase inhibitor, to examine efficacy and tolerability in patients with relapsed/refractory Hodgkin lymphoma (HL) with ≤ 5 prior therapies. The primary endpoint was the objective response rate (ORR), with secondary endpoints of progression-free survival (PFS), overall survival (OS), safety and tolerability. A two-stage design was used for patient accrual. Twenty-five eligible patients were accrued in the first stage. Median time on treatment was 3.8 months. The ORR was 4% (one partial response). Median PFS was 4.8 months. The drug was well tolerated. The second stage of accrual was not opened due to few objective responses. Oral vorinostat has limited single-agent activity in relapsed/refractory HL. There was one partial response, while seven other patients had stable disease for > 1 year, including two with stable disease for nearly 3 years, suggesting that further studies in combination with other active agents in this setting may be warranted.

KW - Lymphoma and Hodgkin disease

KW - Pharmacotherapeutics

KW - Signaling therapies

UR - http://www.scopus.com/inward/record.url?scp=84856115538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856115538&partnerID=8YFLogxK

U2 - 10.3109/10428194.2011.608448

DO - 10.3109/10428194.2011.608448

M3 - Article

C2 - 21823829

AN - SCOPUS:84856115538

VL - 53

SP - 259

EP - 262

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 2

ER -